EMA Expects To Issue Recommendation On Pfizer's Anti-COVID Drug Paxlovid Before 2022

EMA Expects to Issue Recommendation on Pfizer's Anti-COVID Drug Paxlovid Before 2022

The European Medicines Agency (EMA) expects to issue recommendation for the use of Pfizer's anti-coronavirus drug Paxlovid before year-end, Dr. Marco Cavaleri, the head of Biological Health Threats and Vaccines Strategy at the EMA, said on Thursday

MOSCOW (UrduPoint News / Sputnik - 09th December, 2021) The European Medicines Agency (EMA) expects to issue recommendation for the use of Pfizer's anti-coronavirus drug Paxlovid before year-end, Dr. Marco Cavaleri, the head of Biological Health Threats and Vaccines Strategy at the EMA, said on Thursday.

"Our recommendation to support emergence use for Paxlovid, similarly to (Merck's) Molnupiravir, is expected to take place before the end of this year," Cavaleri said.